ABSTRACT
Successful translation of magnetic nanoparticles (MNPs) for clinical use requires many years of development and iterative design to optimize in vivo characteristics. Positron Emission Tomography (PET) and Single Photon Emission Computed Tomography (SPECT) are nuclear imaging techniques which offer unparalleled noninvasive imaging sensitivity. Radiolabeling of nanoparticles (NPs) with positron or gamma emitting radioisotopes allows for the collection of key in vivo information including clearance properties and target tissue accumulation concentration to aid in design optimization and expedite clinical translation. The following chapter details both the advantages of using nuclear imaging for researchers designing MNPs for biomedical applications and offers a roadmap for developing and imaging radiolabeled NPs.
